Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bernhard

Showing results (161-170 of 250) with videos related to

Pageof 25
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1988
Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3K T Hogan, C Clayberger, E J Bernhard, et al.
Cancer Research|September 6, 2005
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell linesIn-Ah Kim, Sun-Sik Bae, Annemarie Fernandes, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]L Dupitout, E Tricaud, A Lasserre, et al.
Radiation Oncology (London, England)|March 29, 2012
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivityEmmanouil Fokas, Michio Yoshimura, Remko Prevo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study GroupC Hürny, J Bernhard, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK)R A Joss, M Bacchi, C Hürny, et al.
Radiation Research|August 19, 2015
Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical TranslationPataje G S Prasanna, Deepa Narayanan, Kory Hallett, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
Environmental Toxicology and Chemistry|October 22, 2013
The rhizotoxicity of metal cations is related to their strength of binding to hard ligandsPeter M Kopittke, Neal W Menzies, Peng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?J Bernhard, B Thürlimann, S F Schmitz, et al.
Pageof 25

Showing results (161-170 of 250) with videos related to

Sort By:
Pageof 25
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1988
Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3K T Hogan, C Clayberger, E J Bernhard, et al.
Cancer Research|September 6, 2005
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell linesIn-Ah Kim, Sun-Sik Bae, Annemarie Fernandes, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]L Dupitout, E Tricaud, A Lasserre, et al.
Radiation Oncology (London, England)|March 29, 2012
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivityEmmanouil Fokas, Michio Yoshimura, Remko Prevo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study GroupC Hürny, J Bernhard, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK)R A Joss, M Bacchi, C Hürny, et al.
Radiation Research|August 19, 2015
Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical TranslationPataje G S Prasanna, Deepa Narayanan, Kory Hallett, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
Environmental Toxicology and Chemistry|October 22, 2013
The rhizotoxicity of metal cations is related to their strength of binding to hard ligandsPeter M Kopittke, Neal W Menzies, Peng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?J Bernhard, B Thürlimann, S F Schmitz, et al.
Pageof 25